The Hidden Economics of Single – Use Assemblies : Beyond Purchase Price to Total Cost of Ownership

The biopharmaceutical industry has witnessed a profound transformation over the past two decades with the widespread adoption of single-use technologies (SUTs). What began as a niche solution for clinical-scale manufacturing has evolved into a mainstream platform supporting commercial production of monoclonal antibodies, vaccines, cell and gene therapies, recombinant proteins, and emerging biologics.

Among the most critical components of this ecosystem are single-use assemblies—customized combinations of tubing, connectors, filters, sensors, manifolds, bags, and fittings designed to facilitate sterile fluid transfer and process integration. Traditionally, procurement teams evaluated these assemblies primarily through the lens of purchase price. However, the increasing complexity of biologics manufacturing, heightened regulatory expectations, and lessons learned from pandemic-era supply chain disruptions have fundamentally changed how organizations assess value.

Today, leading biopharmaceutical manufacturers are shifting toward a Total Cost of Ownership (TCO) approach that considers the complete economic impact of a single-use assembly throughout its lifecycle. Under this framework, factors such as contamination risk, downtime, changeover efficiency, inventory management, qualification requirements, lead times, and supply chain resilience often outweigh the initial purchase price. The most economical assembly is rarely the cheapest assembly. Rather, it is the solution that minimizes risk, maximizes operational efficiency, and delivers the greatest value across the entire manufacturing process.

The evolution from purchase price to lifecycle economics
Historically, procurement departments were evaluated based on their ability to negotiate lower prices and generate annual cost savings. As a result, purchasing decisions often focused on comparing quotations from multiple suppliers and selecting the lowest-cost option. This approach may be appropriate for commodity products, but it becomes increasingly dangerous when applied to critical bioprocess components.

A single-use assembly is not merely a collection of plastic parts. It is a process-enabling system that directly influences product quality, manufacturing throughput, regulatory compliance, and operational continuity. Consider two assemblies that differ in price. On paper, selecting the lower-cost option appears financially prudent. However, if the cheaper assembly contributes to a production delay, requires additional validation activities, or increases contamination risk, the resulting financial consequences can exceed hundreds of thousands—or even millions—of rupees.

Consequently, procurement organizations are increasingly collaborating with engineering, quality, manufacturing, and supply chain teams to evaluate lifecycle economics rather than purchase price alone. This shift represents a broader transformation from transactional procurement toward strategic value-based sourcing.

Understanding total cost of ownership (TCO)
Total Cost of Ownership encompasses every direct and indirect cost associated with acquiring, implementing, operating, maintaining, and eventually replacing a product.

For single-use assemblies, TCO typically includes purchase price, engineering support, qualification and validation costs, change control management, inventory carrying costs, production downtime, contamination risk, supply chain disruption costs, lead-time management, waste disposal costs, operator training, process efficiency impacts, and business continuity risks. When viewed through this comprehensive lens, the purchase price often represents only a small fraction of the total economic impact. A procurement team focused solely on acquisition cost may optimize a single budget line item while inadvertently increasing costs elsewhere in the organization. The TCO framework eliminates this siloed thinking and promotes enterprise-wide value creation.

The cost of contamination – the most expensive failure
Among all economic considerations, contamination risk remains the most significant. In biologics manufacturing, a contaminated batch can lead to product loss, investigation costs, corrective and preventive actions (CAPA), manufacturing delays, regulatory reporting, supply shortages, customer dissatisfaction, and revenue loss.

For commercial biologics, a single batch may be worth crores of rupees. The cost of a failed tubing weld, defective connector, compromised bag film, or assembly leak is negligible compared with the financial consequences of losing an entire batch. Organizations frequently underestimate the hidden economic value of robust assembly design and manufacturing quality.

Critical factors are material consistency (variability in polymer formulations can influence extractable, leachable, mechanical strength, and long-term reliability), manufacturing controls (controlled assembly environments reduce contamination risk and improve reproducibility), sterility assurance (validated sterilization processes significantly lower quality risks), and supplier quality systems (strong quality management systems reduce deviations and improve process consistency).

The premium paid for superior quality components often represents an insurance policy against catastrophic manufacturing failures. When contamination costs are incorporated into TCO calculations, the lowest-priced option frequently becomes the most expensive.

Downtime reduction – the hidden capacity multiplier
Manufacturing downtime is one of the least visible but most costly operational inefficiencies. Biopharmaceutical facilities are capital-intensive assets designed to maximize production throughput. Every hour of downtime reduces utilization and increases the cost of goods produced.

Downtime can arise from assembly failures, incorrect configurations, missing components, delayed deliveries, operator errors, installation challenges, and quality investigations. Single-use assemblies play a direct role in minimizing these risks. Assemblies designed for ease of installation, error-proofing, and operational reliability reduce interruptions and improve manufacturing continuity.

Considering a biologics facility operating multiple production suites – if improved assembly reliability reduces downtime by only 1–2%, the resulting increase in manufacturing output can generate substantial financial returns. In many cases, the value of recovered production time exceeds annual procurement savings achieved through aggressive price negotiations. Viewed strategically, high-performance assemblies function as productivity enhancers rather than consumable expenses.

Changeover efficiency – accelerating manufacturing agility
The biopharmaceutical industry increasingly demands flexibility. Contract Development and Manufacturing Organizations (CDMOs), multiproduct facilities, and emerging therapy manufacturers routinely switch between products, batches, and process configurations.

Traditional stainless-steel systems require extensive cleaning, cleaning validation, sterilization, and turnaround activities. Single-use assemblies dramatically simplify these transitions. Reduced turnaround time, increased facility utilization, lower labour requirements, faster campaign changes, reduced cleaning validation costs, and improved manufacturing flexibility offer significant economic benefits. However, not all assemblies deliver equal value.

Engineering decisions such as connector standardization, modular assembly design and ergonomic configuration, labelling strategy and pre-assembled manifolds can significantly reduce setup complexity and operator intervention. Even small reductions in changeover time accumulate over dozens or hundreds of manufacturing campaigns annually. Organizations increasingly quantify these benefits as part of TCO analyses, recognizing that operational agility directly influences profitability.

Inventory optimization – reducing working capital without increasing risk
Inventory management represents another frequently overlooked cost category. To protect against supply disruptions, manufacturers often maintain substantial safety stock of critical assemblies. While this strategy improves supply security, it also creates hidden costs of warehousing expenses, capital tied up in inventory, product obsolescence, expiration risks, and forecasting inaccuracies. A fragmented assembly portfolio containing hundreds of unique configurations compounds these challenges.

Strategic standardization can significantly reduce inventory requirements. They can drive SKU rationalization (fewer assembly variants simplify planning and procurement), improved forecast accuracy (standardized components improve demand predictability), reduced storage requirements (consolidated inventories require less warehouse space), and lower obsolescence risk (standard components remain usable across multiple processes).

The financial impact is often substantial. Organizations may reduce inventory carrying costs while simultaneously improving supply reliability. The resulting improvements in cash flow and working capital efficiency contribute directly to corporate financial performance.

Qualification and validation costs – the silent budget drain
Qualification activities represent one of the most underestimated contributors to TCO. Every new assembly introduced into a regulated manufacturing environment requires varying degrees of supplier qualification, material review, risk assessment, extractable evaluation, documentation review, process validation, and change control approval.

These activities consume significant engineering, quality, regulatory, and manufacturing resources. The true cost extends far beyond laboratory testing. Highly trained personnel may spend hundreds of hours evaluating a single component change. Supplier instability further amplifies these costs. Frequent design modifications, material substitutions, or manufacturing changes can trigger requalification exercises, additional testing, regulatory assessments, and customer notifications.

Organizations increasingly recognize that supplier consistency and technical documentation quality have measurable economic value. A supplier with robust change management processes may command a premium price yet deliver substantially lower lifecycle costs.

Lead-time impact – the economics of time
The pandemic fundamentally changed how the industry views lead times. Prior to 2020, many organizations optimized inventory levels assuming relatively predictable supply availability. The global shortages experienced during COVID-19 exposed the vulnerability of these assumptions.

Extended lead times create several financial burdens related to larger safety stock requirements, increased inventory carrying costs, production scheduling challenges, delayed product launches, and reduced operational flexibility. Lead time is therefore not merely a logistics metric; it is a financial variable.

A supplier capable of consistently delivering assemblies within shorter lead times creates value by reducing working capital requirements, improving production planning, supporting faster market responsiveness, and lowering inventory risk.

Regional manufacturing capabilities are increasingly viewed as strategic assets because they shorten supply chains and reduce transportation uncertainty. As biologics demand continues to grow globally, lead-time performance will become an even more important differentiator.

Supply chain risk – the new economic reality
Perhaps the most profound lesson from recent years is that supply chain resilience has economic value. Historically, procurement strategies emphasized supplier consolidation to maximize purchasing leverage. While consolidation can generate short-term savings, it also creates concentration risk.

Single-source dependencies can expose manufacturers to raw material shortages, geopolitical disruptions, transportation delays, natural disasters, regulatory actions, and capacity constraints. The financial consequences can be severe. A production shutdown caused by unavailable assemblies can cost millions of dollars in lost revenue and delayed product supply. Consequently, leading organizations now evaluate supply chain resilience using criteria such as geographic diversification, manufacturing redundancy, supplier financial stability, regional inventory availability, vertical integration capabilities, and risk management maturity.

The value of resilience is difficult to quantify until disruption occurs. However, the events of recent years have demonstrated that supply security often outweighs marginal purchase price differences. Supply chain risk has evolved from an operational concern into a boardroom-level strategic issue.

Engineering decisions as financial decisions
One of the most important shifts occurring within the industry is the recognition that engineering decisions are financial decisions. Historically, engineering teams focused on technical performance while procurement focused on cost. Today, these functions are increasingly interconnected. Engineering choices regarding tubing materials, connector technologies, filter configurations, assembly architecture, standardization strategies, and supplier selection directly influence manufacturing productivity, quality outcomes, regulatory compliance, inventory requirements, supply chain resilience, and total lifecycle costs.

For example, selecting a more robust connector system may increase assembly cost by a few percentage points. However, if that decision reduces installation errors, contamination risk, and downtime, the resulting economic benefits can be enormous. Forward-thinking organizations increasingly employ cross-functional TCO models that evaluate both technical and financial impacts before making sourcing decisions.

The rise of strategic procurement
The procurement function itself is evolving. Modern procurement leaders are no longer measured solely by purchase price reductions. Instead, they are evaluated on broader business outcomes including supply continuity, risk mitigation, cost of goods reduction, operational efficiency, supplier innovation, sustainability, and lifecycle value creation.

This transformation requires deeper collaboration among procurement, engineering, quality, manufacturing, and supply chain teams. The most successful organizations establish integrated decision-making frameworks that balance cost, quality, risk, and performance. Such approaches generate sustainable competitive advantage while reducing long-term ownership costs.

Future outlook – from commodity thinking to value engineering
As biologics manufacturing becomes increasingly sophisticated, the industry will continue moving away from commodity-based procurement models. Several trends will accelerate this shift, specifically expansion of cell and gene therapies, increased process intensification, greater manufacturing flexibility requirements, digital supply chain integration, rising regulatory expectations, regional manufacturing strategies, and sustainability initiatives.

These developments will increase the strategic importance of single-use assemblies. Manufacturers will increasingly seek partners capable of delivering design optimization, supply chain resilience, technical expertise, documentation excellence, regional support, and innovation capabilities. The future competitive landscape will favour suppliers that demonstrate measurable contributions to lifecycle economics rather than simply offering the lowest price.

Conclusion
The hidden economics of single-use assemblies extend far beyond purchase price. While acquisition cost remains important, it represents only one element of a much larger economic equation.

Contamination prevention, downtime reduction, changeover efficiency, inventory optimization, qualification requirements, lead-time performance, and supply chain resilience all contribute significantly to Total Cost of Ownership. Organizations that continue to evaluate assemblies solely on unit price risk making decisions that increase lifecycle costs and operational vulnerability.

Conversely, manufacturers adopting a comprehensive TCO framework can unlock substantial value through improved productivity, reduced risk, enhanced flexibility, and stronger supply chain performance. The industry is entering an era in which procurement decisions are no longer simply purchasing decisions—they are strategic business decisions with direct implications for financial performance, operational excellence, and competitive advantage.

Ultimately, the question is not, “What does this assembly cost?” but rather, “What value does this assembly create across its entire lifecycle?” Organizations that understand this distinction will be best positioned to thrive in the increasingly complex and competitive biopharmaceutical landscape.

References
• BioPhorum Operations Group (BPOG). Single-Use Systems Best Practices Guide, BioPhorum Publications.
• International Society for Pharmaceutical Engineering (ISPE). Baseline Guide: Biopharmaceutical Manufacturing Facilities, ISPE Publications.
• U.S. Food and Drug Administration (FDA). Guidance for Industry: Process Validation – General Principles and Practices.
• ASTM International. Standards for Single-Use Manufacturing Systems in Biopharmaceutical Applications.
• PDA Technical Report No. 66. Application of Single-Use Systems in Pharmaceutical Manufacturing, Parenteral Drug Association.
• McKinsey & Company. Building Resilient Supply Chains in Life Sciences: Lessons from the Pandemic.
• Deloitte Insights. The Future of Biopharmaceutical Supply Chains and Manufacturing Resilience.
• BioPlan Associates. Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.